Literature DB >> 24815569

Maternal prenatal infection, early susceptibility to illness and adult psychotic experiences: a birth cohort study.

Kim S Betts1, Gail M Williams2, Jacob M Najman3, James Scott4, Rosa Alati5.   

Abstract

BACKGROUND: Existing evidence has established that maternal infection during pregnancy and illness during early life are associated with later schizophrenia. No research has examined how the combination of these prenatal and postnatal exposures is linked to an increased risk to later schizophrenia and psychotic disorders.
METHODS: Participants from the Mater University Study of Pregnancy (MUSP), an Australian based, pre-birth cohort study were examined for lifetime DSM-IV positive psychotic experiences at 21 years by a semi-structured interview. Structural equation modelling was used to derive a general factor of psychotic experiences at age 21. Next, we undertook a number of separate analyses to investigate how prenatal infections and infant illness susceptibility are related to positive psychotic experiences in early adulthood, allowing for tests of moderation and mediation between the two risk factors.
RESULTS: After adjustment for important confounders, infant illness susceptibility was found to play a mediating role in the association between prenatal vaginal infection and later psychotic experiences. Whereby, infant illness susceptibility showed a direct association with psychotic experiences, while prenatal vaginal infection indirectly predicted psychotic experiences via infant illness susceptibility.
CONCLUSION: Our findings suggest that illness susceptibility in early infancy may be central to the relationship between prenatal vaginal infection and later psychotic experiences. Further research is needed to establish the mechanisms that link these prenatal and postnatal exposures with psychotic illness in later life.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Infant illness susceptibility; Mediation; Moderation; Neurodevelopment; Prenatal infections; Psychotic experiences; Structural equation modelling

Mesh:

Year:  2014        PMID: 24815569     DOI: 10.1016/j.schres.2014.04.013

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

1.  Fetal exposure to maternal stress and risk for schizophrenia spectrum disorders among offspring: Differential influences of fetal sex.

Authors:  Anna M Fineberg; Lauren M Ellman; Catherine A Schaefer; Seth D Maxwell; Ling Shen; Nashid H Chaudhury; Aundrea L Cook; Michaeline A Bresnahan; Ezra S Susser; Alan S Brown
Journal:  Psychiatry Res       Date:  2015-12-18       Impact factor: 3.222

Review 2.  Genetic studies of schizophrenia: an update.

Authors:  Jingchun Chen; Fei Cao; Lanfen Liu; Lina Wang; Xiangning Chen
Journal:  Neurosci Bull       Date:  2015-02-06       Impact factor: 5.203

3.  Associations Between Maternal Infection During Pregnancy, Childhood Infections, and the Risk of Subsequent Psychotic Disorder--A Swedish Cohort Study of Nearly 2 Million Individuals.

Authors:  Åsa Blomström; Håkan Karlsson; Renee Gardner; Lena Jörgensen; Cecilia Magnusson; Christina Dalman
Journal:  Schizophr Bull       Date:  2015-08-24       Impact factor: 9.306

Review 4.  Systematic Review of the Neurobiological Relevance of Chemokines to Psychiatric Disorders.

Authors:  Michael J Stuart; Gaurav Singhal; Bernhard T Baune
Journal:  Front Cell Neurosci       Date:  2015-09-10       Impact factor: 5.505

5.  Upper respiratory infection during pregnancy and neurodevelopmental outcomes among offspring.

Authors:  Samantha E Parker; Virginia A Lijewski; Patricia A Janulewicz; Brent R Collett; Matthew L Speltz; Martha M Werler
Journal:  Neurotoxicol Teratol       Date:  2016-06-23       Impact factor: 3.763

6.  Protective Effect of the MCP-1 Gene Haplotype against Schizophrenia.

Authors:  Hana Saoud; Oumaima Inoubli; Sihem Ben Fredj; Mohsen Hassine; Bochra Ben Mohamed; Lotfi Gaha; Besma Bel Hadj Jrad
Journal:  Biomed Res Int       Date:  2019-12-02       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.